Shares of Chinese drug firm Akeso – likened by some Western media outlets to artificial intelligence start-up DeepSeek – rose after the company unveiled clinical-trial data showing that its lung-cancer drug outperformed a highly effective existing treatment.

Advertisement

The data showed that ivonescimab had “a de

📰

Continue Reading on South China Morning Post

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →